KY SR53

UK Markey Cancer Center treated the first person in the United States with ZG006 (Alveltamig), a new immunotherapy for small cell lung cancer, in October 2025 under lead investigator Dr. Zhonglin Hao

ZG006 is an experimental drug that connects disease-fighting T cells to cancer cells, enabling the immune system to attack the cancer when standard therapies have failed

The first patient experienced no side effects from the initial dose and tolerated a second treatment two weeks later; the therapy may also be effective in treating brain metastasis common in small cell lung cancer

Markey Cancer Center was selected as the first U.S. site for this clinical trial due to its status as one of 57 National Cancer Institute-designated Comprehensive Cancer Centers in the nation

The Senate resolution formally celebrates Markey Cancer Center's scientific achievements and directs the Clerk to transmit a copy to Senator Reginald L. Thomas for delivery